Mission Statement, Vision, & Core Values of INmune Bio, Inc. (INMB)

You're looking at INmune Bio, Inc. (INMB), a clinical-stage biotech where the mission statement isn't just a poster on the wall-it's the only thing justifying the intense burn rate and high-stakes clinical development.

With a Q3 2025 net loss of approximately $6.5 million and a cash position of roughly $27.7 million as of September 30, 2025, every stated value and vision point must defintely map to clinical execution.

How do their core values translate into the precision medicine approach that saw XPro™ miss its primary cognitive endpoint in the full Alzheimer's trial, yet still show positive trends in the enriched subgroup of 100 patients with inflammation biomarkers? Understanding these foundational principles is the only way to gauge the long-term viability of their innate immune system platform.

INmune Bio, Inc. (INMB) Overview

INmune Bio, Inc. is a clinical-stage biotechnology company incorporated in 2015, focused on developing treatments that reprogram the innate immune system-your body's first line of defense-to fight diseases like Alzheimer's and cancer. The company's mission centers on developing and delivering innovative immunotherapies that target the root causes of neurodegenerative diseases and cancer, improving the quality of life for patients with debilitating conditions. Their vision is to be a leader in developing these innovative immunotherapies, which means they are constantly pushing the boundaries of what's possible in this complex field.

The core of their work is built on three distinct product platforms, each tackling a different aspect of immune-driven disease. This is a high-risk, high-reward model. Their platforms include the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, featuring XPro1595, which is designed to selectively neutralize soluble TNF (a key driver of chronic inflammation) for neurodegenerative disorders. Also, there is the CORDStrom™ platform, a proprietary cell therapy for conditions like recessive dystrophic epidermolysis bullosa (RDEB), and the INKmune® platform, which primes a patient's natural killer (NK) cells to eliminate minimal residual disease in cancer.

As a clinical-stage company, INmune Bio's sales revenue is minimal, reflecting their focus on research and development (R&D) over commercialization right now. For the trailing 12 months (TTM) ended September 30, 2025, the company reported revenue of only $50,000. To be defintely clear, they reported no revenue for the third quarter of 2025 itself, which is standard for a biotech at this stage. You need to look at their pipeline progress, not their sales, to gauge value.

• Pioneering novel approaches in immunotherapy.
• Advancing clinical development through rigorous trials.
• Focusing on diseases with significant unmet patient needs.

Latest Financial Trajectory and Pipeline Milestones

Looking at the Q3 2025 financial results, which were reported on October 30, 2025, you can see a company actively managing its burn rate while pushing critical trials forward. The net loss for the quarter ended September 30, 2025, was $6.47 million. Here's the quick math: this is a significant improvement from the net loss of $12.09 million reported in the same quarter a year prior. That's a clear sign of disciplined spending, largely driven by a reduction in R&D costs.

The company's cash and cash equivalents stood at approximately $27.7 million as of September 30, 2025. This cash position is crucial because it funds the ongoing clinical development, which is where the real value is being created. For instance, the CORDStrom™ platform successfully completed its first two commercial pilot-scale manufacturing runs, a key step in preparing for regulatory filings. They are on target to file a Marketing Authorization Application (MAA) in Europe in mid-2026, followed by an anticipated Biologics License Application (BLA) with the FDA.

Also, the INKmune® platform's CARE-PC trial met its primary endpoint and two secondary endpoints, a strong signal for its potential in metastatic castration-resistant prostate cancer. Still, you have to be a realist: the Phase 2 MINDFuL trial for XPro1595 in Alzheimer's disease missed its primary cognitive endpoints, but it did show clinical benefits in a subgroup of patients with high inflammation. This is why you invest in platforms, not just single products.

A Leader in Innate Immunity Reprogramming

INmune Bio is positioning itself as a leader not by selling drugs today, but by pioneering a new paradigm in medicine: reprogramming the innate immune system. Most traditional immunotherapies focus on suppressing the immune system to treat inflammation, but INmune Bio is focused on restoring its function. This distinction is what makes them a key player in the biotech industry's high-growth, high-risk immunotherapy segment.

Their multi-platform approach-targeting neuroinflammation with XPro1595, cancer with INKmune®, and rare diseases with CORDStrom™-demonstrates a broad, strategic commitment to this novel mechanism of action. This is a company betting big on the idea that chronic inflammation is the common denominator in many severe diseases. To see how this strategy is resonating with institutional money and smart investors, you should find out more below to understand why INmune Bio is successful. Exploring INmune Bio, Inc. (INMB) Investor Profile: Who's Buying and Why?

INmune Bio, Inc. (INMB) Mission Statement

You're looking for the bedrock of INmune Bio, Inc.'s strategy-the mission statement. For a clinical-stage biotech, this isn't just a marketing line; it's the long-term blueprint for capital allocation and R&D focus. The company's mission is clear: to develop and deliver innovative immunotherapies that target the innate immune system to fight devastating diseases like Alzheimer's and cancer, ultimately improving patients' quality of life. This mission guides every dollar of their R&D spend and every clinical trial design.

In the first nine months of 2025 alone, INmune Bio has committed significant capital to this mission, with research and development expenses totaling approximately $12.5 million ($7.6 million in Q1 and $4.9 million in Q3). This is a focused, high-stakes bet on a novel mechanism, and it's what you need to track.

• Guides R&D investment and pipeline priorities.
• Focuses on innate immunity for complex diseases.
• Defines long-term shareholder value creation.

Core Component 1: Scientific Innovation via Innate Immunity

The first core component is the focus on the innate immune system. This is the body's first line of defense, and INmune Bio believes reprogramming it-not just suppressing it-is the key to treating chronic inflammation and disease. Their lead asset, XPro1595, embodies this, as it's a selective soluble TNF (sTNF) neutralizer that targets the damaging, inflammatory form of TNF-alpha while sparing the reparative form. This is a precision medicine approach, and it's defintely more complex than a broad-spectrum drug.

This scientific commitment is supported by their active pipeline. For example, the Phase 2 MINDFuL trial for XPro1595 in Early Alzheimer's Disease with inflammation (ADi) enrolled 208 patients, exceeding the initial target of 201. This level of commitment to a novel mechanism shows they are serious about pioneering new approaches, not just following old ones. You can learn more about the investors who back this high-risk, high-reward strategy by Exploring INmune Bio, Inc. (INMB) Investor Profile: Who's Buying and Why?

Core Component 2: Addressing High-Unmet Medical Needs

The company's mission zeroes in on diseases with limited effective treatments: neurodegenerative disorders and cancer. This isn't a scattergun approach; it's a strategic focus on high-value, high-impact areas. They are tackling Alzheimer's disease, where the Phase 2 XPro1595 results, while not meeting the primary endpoint in the overall population, showed a promising benefit in a predefined subgroup of patients with high inflammatory burden (ADi population, n=100).

Here's the quick math on the potential impact: in the ADi subgroup, XPro1595 demonstrated a slowed cognitive decline on the EMACC endpoint with an effect size of 0.27. They also saw reduced neuropsychiatric symptoms on the NPI (effect size -0.23). These are tangible clinical signals that validate their focus on a specific, under-served patient subset. Their other program, INKmune, is also advancing in a Phase I/II trial for metastatic Castration-Resistant Prostate Cancer, another area of high unmet need.

Core Component 3: Rigorous and Patient-Centric Clinical Execution

A mission is only as good as its execution, especially in biotech. INmune Bio emphasizes a rigorous clinical development approach that prioritizes patient benefit. This means using relevant outcome metrics and matching the drug mechanism to patient biology. A key metric of execution is their cash position to fund these trials: as of September 30, 2025, the company held approximately $27.7 million in cash and cash equivalents.

This financial runway is crucial for advancing their pipeline, including the CORDStrom platform, which is on track for regulatory filings in early 2026 after successful pilot-scale manufacturing runs in Q3 2025. Their focus on safety is equally important; for example, the XPro1595 trial showed a complete absence of ARIA-E or ARIA-H-serious side effects seen with other Alzheimer's drugs-even in high-risk patients. That's the kind of quality control that changes a decision for a partner or a regulator.

INmune Bio, Inc. (INMB) Vision Statement

You're looking at INmune Bio, Inc. (INMB) because their focus on the innate immune system is a genuine differentiator in the crowded biotech space. The company's vision is not a simple tagline; it's a three-part strategic roadmap: to be a leader in developing innovative immunotherapies that significantly improve the lives of patients suffering from neurodegenerative diseases and cancer. This vision directly maps to their clinical pipeline and their financial burn rate in 2025, which is what we need to focus on.

Here's the quick math on their runway: they reported cash and cash equivalents of approximately $27.7 million as of September 30, 2025, following a net loss of about $6.5 million in the third quarter of 2025. That cash position is the fuel for this ambitious vision, so every development milestone is defintely critical.

Pioneering Novel Approaches: Harnessing the Innate Immune System

The first pillar of INmune Bio's vision is pioneering novel approaches. They are not chasing the same targets as everyone else; they are focused on modulating the innate immune system-the body's first line of defense-to fight disease. Their primary platforms, Dominant-Negative Tumor Necrosis Factor (DN-TNF) and Natural Killer (NK) cell priming, are first-in-class therapies, meaning they have no direct competitors with the same mechanism of action (MOA).

This strategy is high-risk, high-reward. For example, their DN-TNF product, XPro™ (XPro1595), aims to selectively neutralize soluble Tumor Necrosis Factor (sTNF), a key driver of neuroinflammation in diseases like Alzheimer's. The Phase 2 MINDFuL trial data, released in Q2 2025, initially missed the primary endpoints in the overall population, but showed a clinically relevant effect size of 0.27 on the EMACC (Early Mild Alzheimer's Cognitive Composite) in a pre-defined, high-inflammation subgroup (n=100). That signal is the evidence that the pioneering MOA is working in the right patient subset, validating their precision medicine approach.

• XPro™ targets neuroinflammation in Alzheimer's Disease.
• INKmune™ primes NK cells to eliminate cancer cells.
• CORDStrom™ addresses chronic inflammation in rare diseases.

Advancing Clinical Development: Pipeline Progress and Financial Burn

The second pillar is advancing clinical development through rigorous trials. Clinical-stage biotech companies are valued on pipeline progress, not revenue, and INmune Bio has been moving its three platforms forward aggressively in 2025. This focus, however, creates a significant cash burn. The net loss for the second quarter of 2025 was approximately $24.5 million, a sharp increase from $9.7 million in Q2 2024, reflecting the cost of completing the Alzheimer's trial.

The good news is that they are hitting milestones. Beyond XPro™, the CORDStrom™ platform, which uses human umbilical cord-derived mesenchymal Stromal/Stem cells (hucMSCs) for conditions like Recessive Dystrophic Epidermolysis Bullosa (RDEB), is on track to file a Marketing Authorization Application (MAA) mid-2026, followed shortly by a Biologics License Application (BLA). This regulatory path is a clear, near-term catalyst. To understand the investor sentiment around these milestones, you should be Exploring INmune Bio, Inc. (INMB) Investor Profile: Who's Buying and Why?

Addressing Unmet Needs: Focusing on Patient Impact

The final, and most empathetic, part of their vision is addressing unmet needs and prioritizing patient benefit. This isn't corporate filler; it's a necessity when you consider their target diseases. Alzheimer's disease, various cancers, and RDEB are all areas with limited, often ineffective, treatment options.

The company's approach to trial design reflects this value: they use enrichment criteria to focus trials on patients most likely to benefit, such as the amyloid-positive, high-inflammation subgroup in the MINDFuL trial. This precision medicine strategy is fiscally smart, as it maximizes the chance of a positive readout, and it's ethically sound, ensuring patients in their trials are those whose biology matches the drug's mechanism. The INKmune™ program, for instance, is in a Phase I/II trial for metastatic castration-resistant prostate cancer, a patient group with a profound unmet need for novel, less toxic treatments.

INmune Bio, Inc. (INMB) Core Values

You're looking for the bedrock of INmune Bio, Inc.'s strategy-the principles that turn a clinical-stage biotech's science into potential shareholder value. As a seasoned analyst, I can tell you their operations in 2025 point to three definitive core values. They aren't just buzzwords; they are the filter for every dollar spent and every trial launched.

Their mission is clear: develop and deliver innovative immunotherapies that target the root causes of neurodegenerative diseases and cancer by reprogramming the patient's innate immune system. The vision is to be a leader in this space, significantly improving patient lives. This focus drives their commitment to innovation, patient needs, and operational rigor.

This company's first core value is a deep commitment to pioneering novel approaches in immunology. They don't follow the crowd; they aim to reprogram the innate immune system (the body's first line of defense) rather than just suppressing it. It's a high-risk, high-reward strategy, but the science is defintely compelling.

The 2025 financial data shows this prioritization. Despite a net loss of approximately $6.5 million in Q3 2025, the company continues to invest heavily in its platform technologies. Their three-platform strategy-Dominant-Negative Tumor Necrosis Factor (DN-TNF), Natural Killer (NK) Cell Priming, and CORDStrom™-is the clearest example of this value in action.

• Focus on sTNF: XPro™ selectively neutralizes soluble TNF, a key driver of neuroinflammation.
• NK Cell Priming: INKmune® converts a patient's own resting NK cells into tumor-killing memory-like NK cells.
• Stem Cell Therapy: CORDStrom™ uses proprietary umbilical cord-derived mesenchymal Stromal/Stem cells for inflammation.

They are betting on novel mechanism of action. You can see how investors are tracking this progress by Exploring INmune Bio, Inc. (INMB) Investor Profile: Who's Buying and Why?

A true biotech value is focusing on diseases where current treatment options are limited, and the patient burden is significant. INmune Bio has consistently demonstrated this by targeting conditions like Alzheimer's disease and Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare, debilitating skin disorder.

The Phase 2 MINDFuL trial for XPro™ in early Alzheimer's disease, which enrolled 208 patients, is a prime example. While the overall trial missed its primary cognitive endpoint in June 2025, the company immediately focused on the pre-defined enriched population-the 50% of patients with two or more biomarkers of inflammation-where XPro™ showed a positive impact. That is a precision medicine approach designed to help the right patient group.

For CORDStrom™, the focus on RDEB, a disease with an estimated 4,000 patients in the US/UK/EU, underscores their commitment to rare diseases. They see a potential peak sales opportunity exceeding $1 billion here, but the immediate driver is solving a critical need for these patients. That's a massive commercial opportunity, but it starts with a humanitarian need.

In the clinical-stage world, rigor and efficiency are what keep the lights on and the pipeline moving. This value is about advancing drug candidates through rigorous trials and managing cash to extend the runway.

In 2025, INmune Bio showed a mixed but ultimately disciplined financial picture. They narrowed their net loss in Q1 2025 to approximately $9.7 million and then again in Q3 2025 to approximately $6.5 million, a significant reduction from the Q3 2024 loss of $12.1 million. They did this by cutting Research and Development expenses to approximately $4.9 million in Q3 2025, down from $10.1 million in Q3 2024, showing a clear effort to optimize spending while key trials mature. Here's the quick math: they cut R&D by over 50% year-over-year in the third quarter.

Operational milestones are just as important:

• Completed two commercial pilot-scale manufacturing runs for CORDStrom™ in Q3 2025, preparing for regulatory filings.
• Met the primary safety endpoint for INKmune® in the Phase I portion of the metastatic prostate cancer trial.
• Planned an End of Phase 2 meeting with the FDA, EMA, and MHRA in October 2025 for XPro™ to discuss the path to approval.

As of September 30, 2025, the company had cash and cash equivalents of approximately $27.7 million. This cash position is critical, especially following the Q2 2025 net loss of approximately $24.5 million, which was higher than the prior year. They need to be incredibly precise with their remaining capital to hit the mid-2026 MAA/BLA filing target for CORDStrom™.